This relatively low OS may be attributed to a high rate of patients with peritoneal metastasis, limited access to optimal modern therapies among patients diagnosed in earlier years, a high frequency of KRAS and BRAF mutations, and a limited number of metastasectomies. The treatment of metastatic colon cancer has improved considerably today, especially with the addition of anti-vascular endothelial growth factor (VEGF) and anti-epidermal growth factor (EGFR) antibodies to effective combination chemotherapy as a result of widespread molecular analysis. This evidence concerns the gene KRAS and metastasis.